v3.22.2.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Preferred stock, par value (in dollars per share) $ 0.005 $ 0.005
Current assets:    
Cash and cash equivalents $ 553,754 $ 1,844,732
Short-term investments 163,105 134,603
Accounts receivable 218,334 216,183
Prepaid expenses 247,003 981,895
Contract asset 196,422 132,572
Other current assets 289,991 837,358
Total current assets 1,668,609 4,147,343
Non-current assets:    
Operating lease right-of-use assets 1,060,579 964,331
Restricted cash 0 5,000,000
Goodwill 9,267,007 9,267,007
Intangible assets, net 1,353,562 1,580,980
Property and equipment, net 184,456 201,901
Total non-current assets 11,865,604 17,014,219
Assets of discontinued operation 8,123 8,123
Total assets 13,542,336 21,169,685
Current liabilities:    
Accounts payable and accrued expenses 11,677,761 5,715,956
Current portion of operating lease liabilities 364,830 254,998
Deferred revenue 550,215 373,468
Stock issuances due 681,028 325,828
Notes payable 6,396,486 4,575,000
Total current liabilities 19,670,320 11,245,250
Operating lease liabilities, net of current portion 793,289 806,140
Long-term debt 0 10,625,000
Total long-term liabilities 793,289 11,431,140
Liabilities of discontinued operation 63 63
Total liabilities 20,463,672 22,676,453
Stockholders’ equity (deficit):    
Preferred stock, $.005 par value; 1,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of June 30, 2022 and December 31, 2021 0 0
Common stock, $.005 par value; 150,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 49,641,362 shares issued and outstanding as of June 30, 2022 and 35,484,106 shares issued and outstanding as of December 31, 2021 248,208 177,421
Additional paid-in capital 133,464,596 127,743,333
Accumulated other comprehensive income (loss) 25,169 (6,651)
Accumulated deficit (140,726,745) (129,482,141)
Total Statera Biopharma, Inc. stockholders’ deficit (6,988,772) (1,568,038)
Noncontrolling interest in stockholders’ equity 67,436 61,270
Total stockholders’ deficit (6,921,336) (1,506,768)
Total liabilities and stockholders’ deficit $ 13,542,336 $ 21,169,685